STAT3 and metastatic malignant neoplasm in the lymph nodes: Other studies note that STAT3 was highly expressed in over 50% of NSCLCs, and an increased STAT3 expression level acted as a poor prognosis biomarker, predicting poor differentiation of cancer cells, lymph node metastasis, a low survival rate, and drug resistance [23, 24, 25, 26].